Rapid tests such as Legipid®, Biotica's rapid detection test for Legionella, take on greater importance in the face of the Covid19 pandemic

The use of rapid diagnostic tests has become a priority in response to the Covid-19 pandemic. Not only in the detection of this virus, but also in the detection of other bacteria such as Legionella, which causes severe pulmonary pneumonia and can lead to serious complications for patients.

In this context, in which it is more critical than ever to act with a rapid and objective analysis, the company Biotics based in our facilities highlights the innovation offered by Legipid®, the rapid Legionella detection test developed by this biotechnology firm, which provides results in one hour, eliminating the 10 to 14 day wait of conventional methodology and significantly reducing the risk of exposure and contagion of healthcare personnel and patients.

Thus, this test, which also reduces the rate of inconclusive results, takes on special importance at the current time, due to the greater influx of sick people to facilities such as hospitals, medicalized hotels or nursing homes, so prevention plans and control of legionellosis must be as fast and efficient as possible. Especially in our country, where the incidence of Legionella is well above the European average according to a recent report by the Carlos III Health Institute, which states that declared cases of legionellosis in Spain have increased by 57%.

About Legipid®

Legipid® is the only rapid method with international AOAC-RI certification. It has a technology based on antibodies, of high sensitivity, but low cost, whose application manages to quantify this bacteria in complicated samples, where the presence of other microorganisms prevents it from being detected normally.

In addition, it is used by public administrations in the resolution of outbreaks of legionellosis, it is included in the UNE100030 standard and has been the basis for the development of the first automated Legionella equipment. Legiolab®